Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV-CSI: PEP in Coronary Stent Implantation
NCT04327635Phase 1Completed
- Start
- Nov 2021
- Primary completion
- Oct 2025
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of purified exosome product in myocardial infarction (MI). Primary endpoint: Dose Limiting Toxicities and Maximum Tolerated Dose. Started Nov 2021; status: completed.
02
Drugs
purified exosome product
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT04327635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04327635.